RBC cut its target from $48 to $45 and still calls the shares speculative risk, but kept its Outperform rating. These mixed analyst views report no business change, so the company's outlook is unchanged.
The lower target is a caution, but the kept Outperform rating is a positive signal. The speculative-risk label adds caution. The report does not say IDEAYA's business changed, so these mixed views leave its outlook unchanged.
Follow IDEAYA Biosciences, Inc. (IDYA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IDYA